paclitaxel has been researched along with Sclerosis, Systemic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chanloung, W; Kasitanon, N; Ketpueak, T; Louthrenoo, W; Nan, KN; Pongsananurak, C | 1 |
| DiCaudo, DJ; Farhey, Y; Griffing, WL; Martorano, LM; Trotter, SC; Winkelmann, JC; Winkelmann, RR; Yiannias, JA | 1 |
| Fehr, M; Hafner, J; Läuchli, S; Trüeb, RM | 1 |
| Bugatti, L; Cerioni, A; De Angelis, R; Del Medico, P; Filosa, G | 1 |
| Farrant, PB; Gore, M; Mortimer, PS | 1 |
| Dong, C; Goldschmidt-Clermont, PJ; Hummers, L; Liu, X; Wang, T; Wigley, FM; Zhu, S | 1 |
3 review(s) available for paclitaxel and Sclerosis, Systemic
| Article | Year |
|---|---|
Paclitaxel-induced diffuse scleroderma with possible scleroderma-renal crisis: a case report and literature review of taxanes-induced scleroderma.
Topics: Acute Kidney Injury; Erythema; Female; Humans; Male; Paclitaxel; Scleroderma, Diffuse; Scleroderma, Localized; Scleroderma, Systemic; Taxoids | 2022 |
Paclitaxel-induced diffuse cutaneous sclerosis: a case with associated esophageal dysmotility, Raynaud's phenomenon, and myositis.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Chemotherapy, Adjuvant; Drug Therapy, Combination; Esophageal Motility Disorders; Female; Humans; Immunohistochemistry; Middle Aged; Myositis; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Prognosis; Raynaud Disease; Risk Assessment; Scleroderma, Systemic; Treatment Outcome | 2016 |
Scleroderma and the taxanes. Is there really a link?
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Eruptions; Female; Humans; Middle Aged; Paclitaxel; Scleroderma, Systemic | 2004 |
3 other study(ies) available for paclitaxel and Sclerosis, Systemic
| Article | Year |
|---|---|
Scleroderma-like drug reaction to paclitaxel (Taxol).
Topics: Aged; Antineoplastic Agents, Phytogenic; Drug Eruptions; Female; Humans; Paclitaxel; Scleroderma, Systemic | 2002 |
Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Capillaries; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Scleroderma, Systemic; Skin | 2003 |
Paclitaxel modulates TGFbeta signaling in scleroderma skin grafts in immunodeficient mice.
Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Biopsy; Dose-Response Relationship, Drug; Female; Fibrosis; Humans; Male; Mice; Mice, SCID; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Phenotype; Scleroderma, Systemic; Signal Transduction; Smad Proteins; Transforming Growth Factor beta; Transplantation, Heterologous | 2005 |